Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP505, to US FDA

1.Date of occurrence of the event:2022/12/19 2.New drug name or code: Bispecific Antibody, AP505 3.Indication:Bispecific antibody AP505 is a novel cancer immunotherapy developed by AP Biosciences(hereinafter referred to as APBio). It suppresses tumor growth through dual-blockade of PD-L1 and VEGF signaling pathways, and therefore, avoids immune escape of tumor cells and inhibits angiogenesis at the […]